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17 Microtubule interfering agents (MIAs) are anti-tumor drugs that inhibit microtubule
18 dynamics, while kinesin spindle protein (KSP) inhibitors are substances that block the
19 formation of the bipolar spindle duringmitosis. All these compounds cause G2/M arrest and
20 cell death. Using 2D–PAGE followedbyNano-LC-ESI-Q-ToF analysis, we found thatMIAs such
21 as vincristine (Oncovin) or paclitaxel (Taxol) and KSP inhibitors such as S-tritil-L-cysteine
22 induce the phosphorylation of the nuclear protein p54nrb in HeLa cells. Furthermore, we
demonstrate that cisplatin (Platinol), an anti-tumor drug that does not cause M arrest, does
not induce this modification. We show that the G2/M arrest induced by the MIAs is required
for p54nrb phosphorylation. Finally, we demonstrate that CDK activity is required for MIA-
induced phosphorylation of p54nrb.
© 2008 Elsevier B.V. All rights reserved.
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39 1. Introduction
40 Microtubule dynamics is an important process for many
41 cellular events, especially for cell division where the micro-
42 tubule architecture suffers intense modifications. This impli-
43 cation in cell divisionmakesmicrotubules a relevant target for
44 anti-cancer drugs [1].
45Microtubule interfering agents (MIAs) are compounds that
46bind to tubulin and block microtubule dynamics [2]. This
47causes JNK activation [3], Bcl-2 phosphorylation [4], G2/M
48arrest and cell death [3,5]. Nowadays, the most used MIAs for
49cancer treatment are vinca alkaloids (VAs) and taxanes [6].
50VAs are drugs derived from the periwinkle Catharanthus
51roseus. This group comprises natural molecules such as
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52 vincristine and vinblastine and semisynthetic molecules such
53 as vindesine and vinorelbine [7]. These agents inhibit micro-
54 tubule dynamics by binding to the interface of two tubulin
55 heterodimers. This interaction forms a wedge that blocks the
56 polymerization of microtubules [8].
57 Taxanes are drugs derived from the trees Taxus baccata and
58 Taxus brevifolia. This group comprises the natural molecule
59 paclitaxel and the semisynthetic molecule docetaxel. These
60 agents block microtubule dynamics by binding to the taxane
61 binding domain of β-tubulin. This event stabilises the micro-
62 tubule network and inhibits its depolymerization [2].
63 In the last few years, there has been an intense search of
64 new targets for cancer treatment. One of these novel targets is
65 themitotic specific kinesin (KSP)which ismotor protein that is
66 required for the formation of the bipolar spindle during
67 mitosis [9]. Specific KSP inhibitors have been developed.
68 These compounds bind to an allosteric site adjacent to loop
69 5 that is not present in other related kinesins. These drugs also
70 induce G2/M arrest and cell death and some of them, such as
71 ispinesib, are in phase II of clinical trials [10].
72 The protein p54nrb, also known as NonO, is an abundant
73 nuclear component that binds DNA and RNA. This conserved
74 factor is associatedwith thehighly similar protein PSF in several
75 macromolecular complexes thatare implicated inmanynuclear
76 processes [11]. Thus, these proteins regulate transcription [11]
77 and are related with the coupling of transcription and splicing
78 [12]. They also cause the nuclear retention of defective mRNAs
79 [13], increase theDNA topoisomerase I activity [14] and facilitate
80 the formation of the preligation complex during non homo-
81 logous end joining repair [15]. Furthermore, this protein is
82 implicated in cell differentiation [16,17] and its silencing in
83 breast cancer is associated with loss of estrogen receptor alpha
84 expression and increase of tumor-size [18].
85 By using 2D–PAGE and Nano-LC-ESI-Q-ToF analysis we have
86 determined that MIAs and the KSP inhibitor S-tritil-L-cysteine
87 (STLC) induce the phosphorylation of the nuclear protein p54nrb
88 while cisplatin (another anti-tumor drug that does not induce
89 G2/M arrest) does not induce this modification. We demon-
90 strate that the G2/M arrest caused by MIA is required for p54nrb
91 phosphorylation and CDK activity is required for this modifica-
92 tion to take place.
93 2. Materials and methods
95 2.1. Cell culture and treatments
96 HeLa and HEK 293 cells were propagated in phenol-red DMEM
97 (Cambrex) containing 100 µg/mL gentamicin and 10% of heat
98 inactivated fetal bovine serum (FBS) (Cambrex). For experi-
99 ments, cells were transferred to phenol-red freeDMEMcontain-
100 ing 0.5% of charcoal/dextran-treated FBS, 100 µg/mL gentamicin
101 and 4mM L-glutamine. HeLa cells were kept in this medium for
102 three days and treated while HEK 293 cells were transferred to
103 thismediumand treated at the same time. Cellswere incubated
104 with vincristine (Sigma), vinblastine (Sigma), paclitaxel (Sigma),
105 docetaxel (Fluka) and aphidicolin (Sigma) dissolved in ethanol
106 and with cisplatin (Sigma), S-tritil-L-cysteine (Calbiochem), and
107 roscovitine (Calbiochem) were dissolved in DMSO. The final
108 concentrations of ethanol and DMSO were 0.1%.
1092.2. Flow cytometry
110Cells were collected by trypsinization and incubated sequen-
111tially, according to Vindelov's technique in 300 µL of buffer A
112(0.5 mM Tris–HCl pH 7.6, 0.1% Nonidet P-40 v/v, 3.4 mM
113trisodium citrate, 1.5 mM spermine, 30 µg/mL trypsin from
114Sigma) for 10min, in 250 µL of buffer B (0.5mMTris–HCl pH 7.6,
1150.1% Nonidet P-40 v/v, 3.4 mM trisodium citrate, 1.5 mM
116spermine, 500 µg/mL trypsin inhibitor from Sigma, 100 µg/mL
117RNase A from Sigma) for 10 min and in 250 µL of buffer C
118(0.5 mM Tris–HCl pH 7.6, 0.1% Nonidet P-40 v/v, 3.4 mM
119trisodium citrate, 4.83 mM spermine, 416 µg/mL propidium
120iodide) for 10 min. Cell cycle was analyzed in a FACscan flow
121cytometer (Becton Dickinson) using ModFYT software.
1222.3. Western blot analysis
123Cell extracts were obtained in Laemmli buffer, heat denatured
124and 5 to 10 µg of protein were electrophoresed on a 15% SDS–
125PAGE. After electrophoresis, proteinswere transferred to PVDF
126membranes (Millipore). Membranes were blocked with TBS/
127Tween-20 supplemented with 5% w/v non-fat milk for 1 h at
128room temperature, then incubated with primary antibody
129overnight at 4 °C, with secondary antibody for 1 h at room
130temperature, and developed with enhanced chemilumines-
131cence reagents (GE-Healthcare). Anti-histone H3 phosphory-
132lated at serine 10 (Santacruz, Cat. sc-8656), anti-β-actin (Sigma,
133Cat. A-5441), anti-rabbit peroxidase (Cell Signaling, Cat. 7074)
134and anti-mouse peroxidase (Sigma, Cat. A-9044) were used at
1351:50,000, 1:20,000, 1:2000 and 1:10,000 dilution respectively.
1362.4. Two-Dimensional Polyacrylamide Gel Electrophoresis
137(2D–PAGE)
1382D–PAGE experiments were carried out as described previously
139[19]. Briefly, cellswere solubilized inUTATHbuffer [7Murea, 2M
140thiourea, 1% Amidosulfobetaine-14, 50 mM 2-Hydroxyethyl
141disulfide (HED), 0.5% IPG buffer pH 3–10 (Bio-Rad)], desalted
142with a desalting spin column (Pierce) and 60 to 100 µg of protein
143were loaded onto a strip holder. First dimensionwas run in 7 cm
144Immobiline™DryStrips pH3–11 (GE-Healthcare) for 12 h at 30V,
145250 Vh at 500 V, 500 Vh at 1000 V and 8000 Vh at 5000 V. For
146second dimension, strips were equilibrated in equilibration
147buffer (6Murea, 30% glycerol, 50mMTris pH6.8, 2%SDS, 0.002%
148bromophenol blue w/v) and run in 10% polyacrylamide gels
149supplemented with 50 mM HED and 6 M urea. For Coomassie
150staining, gelswere fixedwith fixing-solution (20%methanol v/v,
15110% acetic acid v/v) for 24 h, stained with Coomassie-solution
152(0.25% brilliant blue R250w/v, 45%methanol v/v, 10% acetic acid
153v/v) for 2 h and distained with fixing-solution for 24 h. For
154Western analysis, proteins were transferred to PVDF mem-
155branes and processed as described previously. Anti-p54nrb (BD
156Biosciences, Cat. 611278), and anti-mouse peroxidase (Sigma,
157Cat. A-9044) were used at 1:10,000 dilution.
1582.5. Trypsin digestion, mass spectrometry and bio-
159informatics analysis of data
160Gel spots were subjected to in-gel digestion (http://msfacility.
161ucsf.edu/ingel.html) with trypsin (porcine, side-chain
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162 protected, Promega). Briefly, protein spots were washed
163 twice with 50% acetonitrile (ACN) in 25 mM ammonium
164 bicarbonate (NH4HCO3) and vacuum-dried. Then, gel pieces
165 were rehydrated in 25 µl of digestion buffer (10 ng/µl trypsin
166 in 25 mM NH4HCO3) for 10 min at 4 °C. The digestion was
167 performed for 4 h at 37 °C. Tryptic peptides were extracted
168 twice with 50% ACN and 5% formic acid. Extracted peptides
169 were vacuum-dried and resuspended in 10 µl of 0.1% formic
170 acid in water. The digests were separated by nanoflow
171 liquid chromatography using a 100-µm×150-mm reverse-
172 phase Ultra 120-µm C18Q column (Peeke Scientific, Redwood
173 City, CA) at a flow rate of 350 nl/min in an Eksigent high
174 performance liquid chromatography system equipped with a
175 FAMOS autosampler (both Dionex-LC Packings, San Fran-
176 cisco, CA). Mobile phase A was 0.1% formic acid in water, and
177 mobile phase B was 0.1% formic acid in ACN. Following
178 equilibration of the column in 2% solvent B, approximately
179 one-tenth of each digest (1 µl) was injected, and then the
180 organic content of themobile phase was increased linearly to
181 40% over 30 min and then to 50% in 3 min. The liquid
182 chromatography elute was coupled to a QSTAR-ELITE tan-
183dem mass spectrometer (Applied Biosystems/MDS Sciex,
184Toronto, CA). In every cycle, a 0.5 s of MS acquisition was
185followed by a maximum of 1.5 s of collision-induced-
186dissociation (CID) acquisition for each of the 3 most intense
187multiply charged peaks that were not previously acquired.
188CID collision energy was automatically determined based
189upon peptide charge and mass to charge (m/z) ratio. Protein
190Prospector 4.25.4 software (UCSF/ San Francisco, CA) [20] was
191used to analyze the mass spectra. Initial peptide tolerances
192in MS and MS/MS modes were 200 ppm and 0.2 Da,
193respectively. The data were searched against Swiss Prot
194database from 2007.04.19. Trypsin was designated as pro-
195tease and 1 missed cleavage was allowed. Oxidation of
196methionine, N-terminal acetylation, N-terminal pyrogluta-
197mate, and HED modified cysteine (+76 Da) were allowed as
198variable modifications.
1992.6. “In vitro” dephosphorylation assay
200Paclitaxel treated cells were lysed in UTATH. Once UTATHwas
201removed using a Y-10 microcone (Millipore), proteins were
Fig. 1 –Vincristine effects over the nuclear factor p54nrb in HeLa cells. Cells were treatedwith vehicle (control) or 1 µM vincristine
for 24 h. a) Coomassie staining of a zone of a 2D–PAGE showing the spots of interest. b) Mass spectrometry analysis of spot 1.
(m: oxidizedmethionine) c)Western blot analysis of a 2D–PAGE using specific antibodies against p54nrb. As in a) only the region
of the filter containing spots of interest is shown.
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202 recovered in water and quantified by Bradford assay. 560 µg of
203 protein were dephosphorylated with λ-PPase (New England
204 BioLabs) as described in the manufacturer protocol. After
205 elimination of reaction buffer with a Y-10 microcone, proteins
206 were recovered in UTATH and run in a 2D–PAGE as described
207 above.
2083. Results
2103.1. Identification of p54nrb as a vincristine regulated protein
211To study the proteins altered upon vincristine treatment, HeLa
212cells were treatedwith either vehicle or 1 µM vincristine for 24 h.
213Protein expression after drug treatment was analyzed by 2D–
214PAGE. Observation of the electropherogram showed an up-
215regulated spot, named as 1, in vincristine-treated cells (Fig. 1a).
216For protein identification, spot 1 was excised from the gel and
217digested with trypsin. Then, the peptides obtained were
218analyzed by Nano-LC-ESI-Q-ToF. Finally, Protein Prospector
219analysis of mass spectrometry data determined that the protein
220in spot 1 corresponds to p54nrb with an expectation value of
2212.7×10−4 (Fig. 1b). Western blot analysis revealed 3 groups of
222p54nrb forms. Themost basic group comprises spots a and b; the
223most acidic group comprises spots d, e, f and g. Finally, the
224intermediate group comprises only spot c. Moreover, we
225observed that vincristine up-regulated the groups that comprise
226spots c to g. while had little effect over the basic group (Fig. 1c).
227Spot 1 in Coomassie staining corresponds to a form of p54nrb
228included in the most acidic group (spots d to g). Spot 2 in
229Coomassie staining was also identified as p54nrb by Ms/Ms and
Fig. 2 –Study of p54nrb phosphorylation state after treatment
with vincristine. Cell extracts from vincristine-treated HeLa
cells were incubated in the presence or the absence of λ
PPase as indicated inMaterials andmethods. After incubation,
cell extracts were analyzed by 2D–PAGE followed byWestern
blot using antibodies against p54nrb.
Fig. 3 –Effect of different MIAs on the phosphorylation of nuclear factor p54nrb. HeLa cells were treated for 24 h with vehicle
(control) or 1 µM vincristine (Vc), vinblastine (Vb), paclitaxel (Ptx) or docetaxel (Dtx) as indicated. a) Coomassie staining of
2D–PAGE. b) Flow cytometry analysis of treated cells. Percentage of cells at each cycle stage was calculated considering only
alive cells c) Western blot analysis of treated cell extracts using specific antibodies against phosphorylated histone H3. For this
analysis, β-actin levels were used as a loading control (data not shown).
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230 corresponds to a form included in the most basic group (spots a
231 andb). Vincristine also induced 3 small formsof p54nrb (Spots x, y
232 and z). These spots probably correspond to caspase-processed
233 forms of the protein, since they are not detected in the presence
234 of caspase inhibitors (data not shown).
235 3.2. Identification of some vincristine-induced spots of
236 p54nrb as phosphorylated forms
237 To study if the vincristine-induced forms of p54nrb are phos-
238 phorylated, an “in vitro” dephosphorylation assay was used.
239 Thus, protein extracts from cells treatedwith 1 µM vincristine for
240 24 h were incubated in the presence or in the absence of λ-PPase
241 as described in Materials and methods. Then, extracts were
242 subjected to 2D–PAGE followed byWestern blot analysis. Vincris-
243 tine-induced forms of p54nrb (c,d,e,f, g and h) were undetected
244 after λ-PPase treatment, clearly indicating that these vincristine-
245 induced formsarephosphorylated (Fig. 2). Spotxalsodisappeared
246 after λ-PPase treatment and therefore, this form is also con-
247 sidered as phosphorylated (Fig. 2). The same extracts were run in
248 a 2D–PAGE and gels were stained with Coomassie blue. As ex-
249 pected, spot 1 disappears after PPase treatment (data not shown).
250 3.3. Effect of different microtubule interfering agents over
251 the phosphorylation of p54nrb
252 Since vincristine is a microtubule interfering agent, we have
253 analyzed whether other MIAs that induce G2/M arrest also
254induce the phosphorylation of this protein. Thus, HeLa cells
255were treated with vehicle or 1 µM of vincristine, vinblastine,
256paclitaxel, or docetaxel for 24 h. Then, cell extracts were
257subjected to 2D–PAGE and the gels were stained with
258Coomassie blue. The electropherograms showed that all
259these drugs induced the phosphorylation of p54nrb (Fig. 3a).
260These phosphorylations were also confirmed by Western blot
261analysis (see Fig. 1 of supplementary material). As expected,
262the flow cytometry analysis of these cells showed that all the
263compounds used induced G2/M arrest and cell death (Fig. 3b).
264Furthermore, a Western blot analysis using antibodies against
265the molecular marker phospho-histone H3 indicated that the
266G2/M arrest induced by these agents is at M stage (Fig. 3c).
2673.4. Effect of theKSP inhibitor STLCover the phosphorylation
268of p54nrb
269KSP inhibitors are anti-cancer drugs, still in clinical trials,
270that also induce G2/M arrest and cell death. Thus, we decided
271to analyse whether the KSP inhibitor S-tritil-L-cystein (STLC)
272is able to induce p54nrb phosphorylation. HeLa cells were
273treated with vehicle (control) or 5 µM STLC for 24 h. Then, cells
274were analyzed by flow cytometry and cell extracts were sub-
275jected toWestern blot analysis. As expected, STLC induced cell
276death (Fig. 4b) and M phase arrest (Fig. 4c). More interestingly,
Fig. 4 –S-Tritil-L-cysteine effects on p54nrb phosphorylation
and cell cycle. HeLa cells were treatedwith vehicle (control) or
5 µMS-tritil-L-cystein (STLC) for 24 h. a)Western blot analysis
of 2D–PAGE gels using antibodies against p54nrb. b) Flow
cytometry analysis of treated cells. c) Western blot analysis
using antibodies against histoneH3 phosphorylated. (STLC 1:
1 µM S-tritil-L-cysteine; STLC 2.5: 2.5 µM S-tritil-L-cysteine;
STLC 5: 5 µM S-tritil-L-cysteine).
Fig. 5 –Cisplatin effects on p54nrb phosphorylation and cell
cycle.HeLacellswere treatedwithvehicle (control) or7.5µg/mL
cisplatin for 24 h. a) Western blot analysis of 2D–PAGE gels
using antibodies against p54nrb. b) Flow cytometry analysis of
treated cells. c) Western blot analysis using antibodies against
histone H3 phosphorylated (C: control; Cp 5: 5 µg/mL cisplatin;
Cp 7.5: 7.5 µg/mL cisplatin).
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277 STLC induced the phosphorylation of p54nrb. Further-
278 more, STLC also induced the smaller form z of the protein
279 (Fig. 4a).
280 3.5. Effect of cisplatin over p54nrb phosphorylation
281 Since all tested agents that induce p54nrb phosphorylation also
282 induce M arrest and cell death, we analyzed whether other
283 anti-tumor drugs that induce cell death but not M arrest also
284 trigger this modification. To study this premise, we have used
285 cisplatin, a drug that induces DNA damage. Thus, we treated
286 HeLa cells with vehicle or 7.5 µg/mL cisplatin for 24 h. Flow
287 cytometry analysis confirmed that cisplatin causes cell death
288 (Fig. 5b), whileWestern blot analysis using the specific marker
289 histone H3 phosphorylated at serine 10, showed that this drug
290 does not induce M arrest (Fig. 5c). Moreover, cisplatin caused
291 an increase of the CV coefficient, indicating DNA damage
292 [21] (Fig. 5b). 2D–PAGE analysis demonstrated that cisplatin
293 does not trigger p54nrb phosphorylation. Rather, it appears
294to downregulate the phosphorylated forms of this protein
295(Fig. 5a). This downregulation is coupled to a reduction in the
296number of M phase cells (Fig. 5c). Moreover, we observed that
297cisplatin treatment induced the smaller form z of p54nrb. As
298mentioned above, this is probably a caspase-processed form.
299It has been recently demonstrated that during cisplatin
300induced cell death, p54nrb is processed by caspases [22].
3013.6. p54nrb phosphorylation induced by MIAs requires G2/
302M arrest
303Since only the drugs that produce G2/M arrest also induce
304p54nrb phosphorylation, we analyzed if the G2/M arrest is
305necessary for the induction of phosphorylation. To check this
306option, we used arrested cells at the beginning of S phase, by
307using the DNA polymerase inhibitor aphidicolin. Thus, HeLa
308cells were treated with vehicle, 2 µg/mL aphidicolin, 1 µM
309vincristine, 1 µM paclitaxel or the combination of 2 µg/mL
310aphidicolin with 1 µM vincristine or 1 µM paclitaxel for 24 h.
Fig. 6 –Effect of aphidicolin-induced cell cycle arrest over MIA-induced phosphorylation of p54nrb. HeLa cells were treated with
vehicle (control), 1 µM vincristine (Vc), 1 µM paclitaxel (Ptx), 2 µg/mL aphidicolin (Aph) or the combination of aphidicolin with
1 µM vincristine (Aph+Vc) or 1 µM paclitaxel for 24 h (Aph+Ptx). Aphidicolin was added 24 h before MIA treatment. a) Western
blot analysis of 2D–PAGE gels using antibodies against p54nrb. b) Flow cytometry analysis of treated cells.
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311 Aphidicolin was added 24 h prior to MIA treatment. Then, cell
312 extracts were subjected to 2D–PAGE followed by Western blot.
313 Both MIAs induced the phosphorylation p54nrb. Further-
314 more, paclitaxel also induced the form z of the protein. More
315 interestingly, aphidicolin precluded the phosphorylation of
316 p54nrb induced by vincristine or paclitaxel (Fig. 6a). The treated
317 cells were also analyzed by flow cytometry. Vincristine and
318 paclitaxel induced G2/M arrest, while in cells pretreated with
319 aphidicolin this induction did not occur (Fig. 6b). These results
320 clearly show an association between the induction of G2/M
321 arrest and the p54nrb phosphorylation.
322 3.7. CDKactivity is required forMIA-inducedphosphorylation
323 of p54nrb
324 It has been described that MIAs induce CDK activity and that
325 one of these family of kinases, CDK1, phosphorylates p54nrb
326 during mitosis. Thus, we decided to study whether CDK
327 activity is required for MIA-induced phosphorylation of
328 p54nrb, using the CDK inhibitor roscovitine. HeLa cells were
329 treated with vehicle, 1 µM paclitaxel, 50 µM roscovitine or
330 the combination of 1 µM paclitaxel and 50 µM roscovitine.
331 Paclitaxel was added 24 h before roscovitine. Flow cytometry
332 analysis revealed that paclitaxel induces G2/M arrest and
333 cell death, while no relevant effect was detected after
334 roscovitine treatment (Fig. 7a) The results demonstrate
335 that paclitaxel induces the phosphorylated forms d to g
336 (Fig. 7b). This drug also induces the spots x, y and z which
337 correspond to processed forms of the protein (Fig. 7b).
338 Roscovitine treatment induced p54nrb processing but did not
339 affect its phosphorylation (Fig. 7b). Interestingly, the addition of
340 roscovitine reduced the amount of the phosphorylated forms of
341 p54nrb that are up-regulated by paclitaxel (forms d, e, f, g and x)
342(Fig. 7b). These data indicate that CDK activity is needed in the
343signalling pathway that triggers the MIA-induced phosphoryla-
344tion of p54nrb.
Fig. 7 –Effect of roscovitine-induced inhibition of CDK1 over MIA-induced phosphorylation of p54nrb. HeLa cells were treated
with vehicle (control), 1 µM paclitaxel (Ptx), 50 µM roscovitine (Ros) or the combination of 1 µM paclitaxel and 50 µM roscovitine
(Ptx+Ros) for 6 h. Paclitaxel was added 24 h before roscovitine treatment. a) Flow cytometry analysis of treated cells. b)Western
blot analysis of the treated extracts using antibodies against p54nrb.
Fig. 8 –Effects of vincristine and paclitaxel over p54nrb in HEK
293 cells. Cells were treated with vehicle (control), 1 µM
vincristine or 1 µM paclitaxel for 24 h. a) Cell extracts were
subjected to a 2D–PAGE followed by a Western blot using
antibodies against p54nrb. b) Cell extracts were analysed
by Western blot analysis using antibodies against
phosphorylated histone H3 and β-actin as loading control.
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345 3.8. p54nrb phosphorylation occurs in cells other than HeLa
346 The MIA-induced phosphorylation of p54nrb also occurs in cell
347 lines other than HeLa. We have studied this modification in
348 HEK 293 cells. For this purpose, cells were treated with vehicle
349 (control), 1 µM vincristine or 1 µM paclitaxel for 24 h. Then cell
350 extracts were subjected to 2D–PAGE followed by Western blot
351 analysis. This analysis showed that in HEK 293 cells, vincris-
352 tine and paclitaxel induced the phosphorylation of p54nrb
353 (Fig. 8a). In addition, a Western blot analysis using antibodies
354 against phospho-histone H3 indicated that MIAs also cause M
355 arrest in this cell line (Fig. 8b). The KSP inhibitor STLC also
356 induced the phosphorylation of this nuclear factor (see Fig. 2
357 of supplementary material).
358 4. Discussion
360 VAs and taxanes are the most used and effective drugs in
361 cancer treatment [6]. Nevertheless, the development of drug
362 resistance by the tumoral cells and the severe secondary
363 effects that they cause, are problems that have not been
resolved yet [10]. In order to overcome this unwanted ef-
365 fects, new drugs, such as KSP inhibitors, are being developed
366 [10].
367 MIAs and KSP inhibitors cause G2/M arrest and cell death
368 because they inhibit the separation of sister chromatids
369 during mitosis [2,10]. However, many molecular effects of
370 these drugs are still unknown. The determination of these
371 molecular actions is of great interest since theymay be related
372 to secondary effects and resistance development.
373 In the last few years, the development of proteomic
374 techniques has made 2D–PAGE followed by MS analysis a
375 powerful tool for the analysis of complex protein mixtures.
376 This methodology has been recently used to investigate
377 proteins that are regulated by chemotherapy agents [23,24].
378 In this report, we use this technology to identify several
379 forms of the nuclear factor p54nrb that are detected after
380 vincristine treatment. The incubation of cell extracts from
381 drug treated cells with λ-phosphatase determined that all
382 these forms are phosphorylated. Furthermore, we observed
383 that all MIAs tested induce mitotic arrest and cell death while
384 triggering p54nrb phosphorylation in HeLa and HEK 293 cells.
385 The KSP inhibitor STLC, also induces the phosphorylation of
386 this nuclear factor. On the other hand, the drug cisplatin,
387 which induces cell death but not M arrest, does not induce this
388 modification. Furthermore, when cells are arrested at the
389 beginning of S phase by treatment with the DNA polymerase
390 inhibitor aphidicolin, MIAs are unable to induce G2/M arrest
391 and to trigger the phosphorylation of this nuclear factor. This
392 clearly indicates that the p54nrb phosphorylation induced by
393 these agents occurs during the G2/M phase. Moreover, the
394 treatment with the CDK inhibitor roscovitine downregulates
395 the p54nrb forms that are phosphorylated after MIA treatment.
396 These results indicate that CDK activity is needed for MIA-
397 induced phosphorylation of p54nrb. Roscovitine is a CDK
398 inhibitor that blocks CDK1 and CDK2 with the same specificity
399 and CDK5 to a less extent. In our assay, when roscovitine is
400 added, HeLa cells are already arrested inMphase by a previous
401 24 h pretreatment with paclitaxel. Thus, during roscovitine
402exposure, the phosphorylated p54nrb is dephosphorylated by
403phosphatases in the absence of CDK activity. Since it is
404considered that CDK1 is themain active CDKduring this phase
405of the cell cycle [25], we suggest that CDK1 is responsible for
406p54nrb phosphorylation. This agrees with other data pre-
407viously published. Thus, the MIAs used here have been
408shown to activate CDK1 [26]. It has been described that
409p54nrb can be phosphorylated at threonine 450 [27], a position
410located at a motif targeted by the mitotic kinase CDK1 [28]. It
411has been determined that p54nrb is phosphorylated during
412mitosis by CDK1 [29]. Since the drugs used in this work induce
413mitotic arrest, it is likely that this kinase is responsible for
414the phosphorylation described in this work. We have tried
415to find the peptides containing threonine 450 in our mass
416spectrometry analysis. However we did not find neither the
417phosphorylated peptide in spot 1 nor the unphosphorylated
418one in spot 2 (Fig. 1a).
419During cell division there is a general reduction of mRNA
420levels. However, there are subset of genes (many of them
421closely related to the mitotic process) whose mRNAs are
422increased [30]. The protein p54nrb is a nuclear factor that
423participates in many cellular processes, such as transcription
424and splicing. Thus, it is conceivable that the phosphorylation
425of this protein is required for these changes in mRNA levels to
426occur. Further research is required to establish whether this
427phosphorylation is in the basis of the mitotic process itself, it
428is a consequence of MIA action or, alternatively, of whether it
429is a mechanism of cell resistance to the drugs.
430In summary then, we report that the MIAs vincristine,
431vinblastine, paclitaxel and docetaxel, as well as the KSP
432inhibitor STLC, induce the phosphorylation of the nuclear
433factor p54nrb, while the DNA damaging agent cisplatin does
434not cause this modification and that this phosphorylation is
435associated to the G2/M arrest induced by these drugs.
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